Related Experiment Video

Updated: Aug 30, 2025

Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation
09:09

Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation

Published on: November 10, 2017

8.4K

R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma

Diana Al-Sarayfi1, Frederik O Meeuwes2, Müjde Durmaz3

  • 1Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands.

Blood Cancer Journal
|September 2, 2022
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

573
Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

9.2K

Related Experiment Videos

Last Updated: Aug 30, 2025

Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation
09:09

Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation

Published on: November 10, 2017

8.4K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

573
Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

9.2K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K

Articles linked to this work by shared authors, journal, and citation graph.

Treatment Patterns, Outcomes and Survival Trends in T-Cell Prolymphocytic Leukemia: A Nationwide Population-Based Study in the Netherlands.

European journal of haematology·2026

CD19 CAR T-cell therapy (GLPG5101) for relapsed or refractory B-cell non-Hodgkin lymphoma (ATALANTA-1): phase 1 results from a single-arm, multicentre, phase 1/2 study.

The Lancet. Haematology·2026

Epcoritamab with rituximab and lenalidomide as first-line treatment for follicular lymphoma (EPCORE NHL-2): an open-label, multicentre, phase 1/2 b trial.

The Lancet. Haematology·2026

Hypomethylating agents with venetoclax for newly diagnosed acute myeloid leukemia in patients 65 and older in The Netherlands - A nationwide study of drug usage and treatment outcomes.

European journal of cancer (Oxford, England : 1990)·2026

Molecular Profiling and Disease Tracking of Post-transplant Lymphoproliferative Disorders using Cell-free DNA.

Blood advances·2026

Cell-free DNA genomic and fragmentomic features for early outcome prediction in large B cell lymphoma.

Cell reports. Medicine·2026

Association between diabetic control and progression of monoclonal gammopathy of undetermined significance to multiple myeloma.

Blood cancer journal·2026

Selinexor for myelofibrosis or a drug in search of a disease?

Blood cancer journal·2026

Combination of daratumumab, ixazomib, and lenalidomide with or without dexamethasone for initial therapy of newly diagnosed myeloma.

Blood cancer journal·2026

Detailed immunophenotypic and genetic characterization of bone marrow clonal plasma cells and B-cells in early-stage monoclonal gammopathies.

Blood cancer journal·2026

Baseline Gustave Roussy Immune Score and Survival in Extensive-Stage Small-Cell Lung Cancer Treated with First-Line Chemoimmunotherapy.

Cancer management and research·2026

Prospective Assessment of Short-Term Response and Acute Toxicity With Accelerated Fractionation Radiotherapy Versus Concurrent Chemoradiotherapy in Locally Advanced Cervical Cancer.

Cureus·2026

Dissection of lymph node on longevity in breast and colorectal operation.

Bioinformation·2026

An Evaluation of the Effect of Opioid-Free Anesthesia on Early Quality of Recovery in Patients Undergoing Gynecological Cancer Surgeries: A Randomized Controlled Trial.

Cureus·2026

Engineered bacteria reverses tumor cuproptosis resistance via cancer-associated fibroblast reprogramming for enhanced immunotherapy.

Materials today. Bio·2026

Pan-Ras-In-1 triggers cell wall lysis to eradicate Staphylococcus aureus.

iScience·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us